Robert McNeil has over twenty-seven years experience as an active investor and management participant in seed and early-stage biomedical companies. He founded Sanderling Ventures in 1979 and has served since then as a Managing Director of Sanderling’s six investment partnerships.
Dr. McNeil was the seed investor for Western Technology Ventures, Advanced Cardiovascular Systems (acquired by Guidant Corp.) and Ventitrex (acquired by St. Jude Medical). Dr. McNeil was a founder, Chief Executive Officer and Chairman of Stereotaxis, the Chief Executive Officer and Chairman of ReGen Biologics, and the Chairman of Ista Pharmaceuticals, as well as other entities.
As an active investor, Dr. McNeil has been instrumental in the development of InfraReDx, Athenagen/Zapaq and GeminX. In each case, close relationships with management and careful understanding of the companies’ technologies have allowed successful development of products at very early stage.
Dr. McNeil earned his Ph.D. in the fields of molecular biology, biochemistry and genetics in 1972 from the University of California, Irvine.
